End-of-day quote
Thailand S.E.
23:00:00 30/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.18
THB
|
-.--%
|
|
-5.26%
|
-37.93%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
406
|
372
|
314
|
969.8
|
315.1
|
234.3
|
Enterprise Value (EV)
1 |
803.8
|
754.3
|
746.3
|
1,392
|
755.5
|
667
|
P/E ratio
|
-4.63
x
|
17.1
x
|
16.2
x
|
-33.7
x
|
-5.04
x
|
-0.64
x
|
Yield
|
-
|
-
|
-
|
6.99%
|
-
|
-
|
Capitalization / Revenue
|
1.29
x
|
1.09
x
|
0.94
x
|
2.98
x
|
1.25
x
|
0.75
x
|
EV / Revenue
|
2.55
x
|
2.2
x
|
2.24
x
|
4.27
x
|
2.99
x
|
2.12
x
|
EV / EBITDA
|
-29.3
x
|
8.09
x
|
9.84
x
|
31.5
x
|
104
x
|
35
x
|
EV / FCF
|
11.3
x
|
20.1
x
|
-33.7
x
|
-80
x
|
-5.44
x
|
5.37
x
|
FCF Yield
|
8.84%
|
4.97%
|
-2.97%
|
-1.25%
|
-18.4%
|
18.6%
|
Price to Book
|
0.93
x
|
0.82
x
|
0.66
x
|
2.09
x
|
0.58
x
|
1.9
x
|
Nbr of stocks (in thousands)
|
600,000
|
600,000
|
600,000
|
678,154
|
808,070
|
808,070
|
Reference price
2 |
0.6767
|
0.6200
|
0.5233
|
1.430
|
0.3900
|
0.2900
|
Announcement Date
|
28/02/19
|
27/02/20
|
01/03/21
|
28/02/22
|
27/02/23
|
27/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
315.7
|
342.2
|
332.5
|
325.8
|
253
|
314.3
|
EBITDA
1 |
-27.44
|
93.24
|
75.84
|
44.17
|
7.287
|
19.03
|
EBIT
1 |
-61.53
|
58.15
|
49.92
|
22.49
|
-12.91
|
-5.697
|
Operating Margin
|
-19.49%
|
16.99%
|
15.01%
|
6.9%
|
-5.11%
|
-1.81%
|
Earnings before Tax (EBT)
1 |
-84.72
|
27.5
|
19.1
|
-21.73
|
-54.99
|
-388.4
|
Net income
1 |
-87.67
|
21.76
|
19.33
|
-26.9
|
-55.35
|
-366.7
|
Net margin
|
-27.77%
|
6.36%
|
5.81%
|
-8.26%
|
-21.88%
|
-116.69%
|
EPS
2 |
-0.1461
|
0.0363
|
0.0322
|
-0.0424
|
-0.0774
|
-0.4539
|
Free Cash Flow
1 |
71.04
|
37.52
|
-22.14
|
-17.4
|
-138.8
|
124.3
|
FCF margin
|
22.5%
|
10.97%
|
-6.66%
|
-5.34%
|
-54.85%
|
39.54%
|
FCF Conversion (EBITDA)
|
-
|
40.24%
|
-
|
-
|
-
|
652.92%
|
FCF Conversion (Net income)
|
-
|
172.4%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.1000
|
-
|
-
|
Announcement Date
|
28/02/19
|
27/02/20
|
01/03/21
|
28/02/22
|
27/02/23
|
27/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
398
|
382
|
432
|
422
|
440
|
433
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-14.5
x
|
4.1
x
|
5.7
x
|
9.555
x
|
60.42
x
|
22.73
x
|
Free Cash Flow
1 |
71
|
37.5
|
-22.1
|
-17.4
|
-139
|
124
|
ROE (net income / shareholders' equity)
|
-19%
|
4.51%
|
3.91%
|
-5.74%
|
-11.4%
|
-137%
|
ROA (Net income/ Total Assets)
|
-3.61%
|
3.49%
|
2.88%
|
1.23%
|
-0.7%
|
-0.39%
|
Assets
1 |
2,427
|
623.9
|
670.6
|
-2,187
|
7,944
|
94,084
|
Book Value Per Share
2 |
0.7300
|
0.7600
|
0.7900
|
0.6800
|
0.6800
|
0.1500
|
Cash Flow per Share
2 |
0
|
0.0100
|
0
|
0
|
0
|
0
|
Capex
1 |
8.84
|
21.1
|
47
|
49.5
|
75.7
|
1.91
|
Capex / Sales
|
2.8%
|
6.18%
|
14.13%
|
15.2%
|
29.92%
|
0.61%
|
Announcement Date
|
28/02/19
|
27/02/20
|
01/03/21
|
28/02/22
|
27/02/23
|
27/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -37.93% | 3.95M | | +15.80% | 17.6B | | -12.60% | 2.67B | | -19.65% | 2.64B | | -26.54% | 1.86B | | -10.33% | 1.07B | | -8.09% | 1.05B | | +6.12% | 879M | | +1.24% | 764M | | -18.81% | 757M |
Testing Laboratories
|